Current Report Filing (8-k)
February 28 2022 - 5:06PM
Edgar (US Regulatory)
0001174940
false
--12-31
0001174940
2022-02-25
2022-02-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934.
Date
of Report: February 25, 2022
(Date
of earliest event reported)
Oragenics,
Inc.
(Exact
name of registrant as specified in its charter)
FL |
|
001-32188 |
|
59-3410522 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification
Number) |
4902
Eisenhower Boulevard, Suite 125
Tampa,
FL |
|
33634 |
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock |
|
OGEN |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.03 |
MATERIAL
MODIFICATIONS TO RIGHTS OF SECURITY HOLDERS. |
The
Company’s Board of Directors and the Company’s shareholders, at its reconvened 2020 Annual Meeting on February 25, 2022 (the
“Annual Meeting”), approved amendments to our Amended and Restated Articles of Incorporation to (i) increase the number of
authorized shares of common stock from 200,000,000 shares to 250,000,000 shares and (ii) provide a reduced quorum requirement from a
majority of shares entitled to vote to one-third (1/3) of shares entitled to vote, represented in person or by a proxy, in order to constitute
a meeting of shareholders. The amendments were filed with the Secretary of State of Florida on February 25, 2022.
The
foregoing descriptions are qualified in their entirety by reference to the amendment filed as Exhibit 3.5 to this Current Report on Form
8-K and incorporated herein by reference.
Item
5.02 |
DEPARTURE
OF DIRECTORS OF CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
|
(e)
Shareholder Approval of the 2021 Equity Incentive Plan.
On
February 25, 2022, the Company held its reconvened Annual Meeting. At the Annual Meeting, the shareholders of the Company approved and
ratified the Company’s 2021 Equity Incentive Plan (the “2021 Plan”). The 2021 Plan provides the aggregate number of
shares of Common Stock that may be issued under the 2021 Plan will not exceed the sum of (i) 10,000,000 new shares, (ii) the number of
shares remaining available for the grant of new awards under the 2012 Equity Incentive Plan (the “2012 Plan”) as of immediately
prior to the effective date of the 2021 Plan, and (iii) certain shares subject to outstanding awards granted under the 2012 Plan that
may become available for issuance under the 2021 Plan, as such shares become available from time to time. The shareholders approved the
2021 Plan in accordance with the voting results set forth below under Item 5.07. The 2021 Plan was originally approved by the Company’s
Board of Directors on March 13, 2021, subject to shareholder approval. The 2021 Plan is a successor to the 2012 Plan.
The
material terms of the 2021 Plan were described in the Company’s Proxy (as described in greater detail in the Definitive Proxy Statement
on Schedule 14A, filed with the Securities and Exchange Commission on October 13, 2021 (the “Proxy”)) under the caption “Proposal
V – Approval of the Company’s 2021 Equity Incentive Plan.” The 2021 Plan provides an opportunity for any employee,
officer, director or consultant of the Company, subject to any limitations provided by federal or state securities laws, to receive (i)
incentive stock options (to eligible employees only); (ii) nonqualified stock options; (iii) restricted stock; (iv) stock awards; (v)
shares in performance of services; (vi) other awards; or (vii) any combination of the foregoing. In making such determinations, the Board
of Directors (or the Compensation Committee) may take into account the nature of the services rendered by such person, his or her present
and potential future contribution to the Company’s success, and such other factors as the Board of Directors (or the Compensation
Committee) in its discretion shall deem relevant. Incentive stock options granted under the 2021 Plan are intended to qualify as “incentive
stock options” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “code”). Nonqualified
(non-statutory) stock options granted under the 2021 Plan are not intended to qualify as incentive stock options under the code.
The
above description of the 2021 Plan does not purport to be complete, and is qualified in its entirety by reference to the full text of
the 2021 Plan, which is attached as Exhibit 10.1 hereto and is incorporated by reference into this Item 5.02.
Item
5.03 |
AMENDMENTS
TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR. |
|
The
information set forth in item 3.03 to this Current Report on Form 8-K is incorporated by reference to this Item 5.03.
On
February 25, 2022 the Company’s Board of Directors amended the Company’s Bylaws to reflect the change in the shareholder
meeting quorum that was approved by the Company’s shareholders. The foregoing description is qualified in its entirety by reference
to the amendment filed as Exhibit 3.9 to this Current Report on Form 8-K and incorporated herein by reference.
Item
5.07 |
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
(a)
The 2020 Annual Meeting of shareholders of Oragenics, Inc. was held on February 25, 2022.
(b)
At the 2020 Annual Meeting, the following proposals were voted on by our shareholders:
PROPOSAL
I: Election of Directors.
Dr.
Frederick Telling, Mr. Robert Koski, Mr. Charles Pope, Dr. Alan Dunton and Ms. Kim Murphy were each re-elected as Directors, to serve
until our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation,
removal from office or death. The votes were as follows:
| |
For | | |
Withheld | | |
Broker Non-Votes | |
Dr. Frederick Telling | |
| 35,868,353 | | |
| 3,602,816 | | |
| 18,933,398 | |
Robert Koski | |
| 35,868,232 | | |
| 3,602,937 | | |
| 18,933,398 | |
Charles Pope | |
| 35,580,729 | | |
| 3,890,440 | | |
| 18,933,398 | |
Dr. Alan Dunton | |
| 35,760,922 | | |
| 3,710,247 | | |
| 18,933,398 | |
Kim Murphy | |
| 35,710,196 | | |
| 3,760,973 | | |
| 18,933,398 | |
PROPOSAL
II: To conduct a non-binding advisory vote on executive compensation. The votes were as follows:
FOR | |
| 29,432,643 | |
AGAINST | |
| 8,841,065 | |
ABSTAIN | |
| 1,197,461 | |
BROKER NON-VOTES | |
| 18,933,398 | |
PROPOSAL
III: To approve the adoption of an amendment to our Amended and Restated Articles of Incorporation which will provide a reduced quorum
requirement of one-third (1/3) of shares entitled to be cast, represented in person or by a proxy, in order to constitute a meeting of
shareholders. The votes were as follows:
FOR | |
| 29,407,046 | |
AGAINST | |
| 8,995,303 | |
ABSTAIN | |
| 1,068,820 | |
BROKER NON-VOTES | |
| 18,933,398 | |
PROPOSAL
IV: To approve the adoption of an amendment to our Amended and Restated Articles of Incorporation which will increase the number
of authorized shares of our Common Stock from 200,000,000 shares of Common Stock to 250,000,000 shares of Common Stock. The votes were
as follows:
FOR | |
| 45,330,819 | |
AGAINST | |
| 12,087,216 | |
ABSTAIN | |
| 986,532 | |
PROPOSAL
V: To approve the Company’s 2021 Equity Incentive Plan. The votes were as follows:
FOR | |
| 25,869,095 | |
AGAINST | |
| 12,376,943 | |
ABSTAIN | |
| 1,225,131 | |
BROKER NON-VOTES | |
| 18,933,398 | |
PROPOSAL
VI: Ratification of the selection of Mayer Hoffman McCann P.C. as the Company’s independent auditors for the year ending December
31, 2021. The votes were as follows:
FOR | |
| 52,983,590 | |
AGAINST | |
| 3,134,957 | |
ABSTAIN | |
| 2,286,020 | |
Item
9.01 |
FINANCIAL
STATEMENTS AND EXHIBITS. |
(d)
Exhibits
SIGNATURES
In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized on this 28th day of February, 2022.
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
|
BY: |
/s/
Michael Sullivan |
|
|
Michael Sullivan |
|
|
Chief Financial Officer |
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024